Trigemina Reports Preliminary Results for Phase IIa Clinical Trial in Chronic Daily Headache

SUNNYVALE, Calif.--(BUSINESS WIRE)--Trigemina, Inc. (TI), a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache (CDH). The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

Back to news